Interim report for the period May - July 2010


Oasmia Pharmaceutical AB (publ)

Interim report for the period May - July 2010 



PHASE III STUDY WITH PACCAL® VET COMPLETED


THE QUARTER IN BRIEF May 1 2010 - July 31 2010
•	Consolidated net sales amounted to TSEK 42 (24 657) 
•	Operating income amounted to TSEK -11 216 (10 624)
•	Net income after tax amounted to TSEK -12 090 (9 386)
•	Earnings per share was SEK -0,32 (0,28)
•	Comprehensive income amounted to TSEK -12 090 (9 386)
•	The Phase III study with Paccal® Vet completed
•	Oasmia signs a MSEK 75 SEDA agreement
•	The Oasmia share is listed on NASDAQ OMX


EVENTS AFTER CLOSING DAY 
•	Oasmia appoints Carnegie Investment Bank AB as financial advisor
•	New MSEK 40 credit facility
•	An application for registration of Paccal® Vet has been submitted to EMA
•	Clinical study shows good tolerance for Doxophos® Vet
•	Oasmia revises financial goal after billion dollar deal in the business 
•	Two thirds of the patients are enrolled in the Phase III study with Paclical®
•	The Phase III study with Paccal Vet submitted to FDA.

Attachments

interim report may 1 2010 - july 31 2010.pdf